series-a
Stage
1
Investors
About
Radionetics develops targeted small-molecule radiopharmaceuticals for precision oncology, applying drug discovery and development expertise against novel cancer targets (including GPCRs) to treat solid tumors. The company advances radiopharmaceutical therapies and has entered a strategic agreement with Lilly.
Explore Radionetics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.